Scleroderma — Systemic Sclerosis · Internal Medicine

Internal Medicine · Clinical Specialties

How it begins

Análisis integral de la esclerodermia: vasculopatía obliterativa, fibrosis cutánea y visceral, inmunopatogénesis, autoanticuerpos específicos, afectación pulmonar, crisis renal y estrategias terapéuticas basadas en la evidencia actual.

What it covers

1. Concept and Classification
2. · Classification: Subtypes of Systemic Sclerosis
3. · Special Shapes and Overlaps
4. Epidemiology and Risk Factors
5. · Genetic Factors
6. · Environmental Factors and Triggers
7. Pathogenesis and Immunopathology
8. · Vasculopathy as an Initiating Event
9. · The IFN Signature and the Role of the CXCL4-pDC Axis
10. Raynaud's Phenomenon and Digital Vasculopathy
11. · Pathophysiology of RF in SSc
12. · FR semiology in ES
13. · Vascular Complications: Digital Ulcers and Gangrene
14. · Periungual Capillaroscopy: Essential Diagnostic Tool
15. Skin Affectation
16. · Phases of Cutaneous Fibrosis
17. · Quantitative Evaluation: Modified Rodnan Skin Score (mRSS)
18. · Specific Skin Manifestations
19. Aparato Locomotor
20. · Arthritis and Arthralgia
21. · Contractures and Acrosteolysis
22. · Myositis and Myopathy
23. Pulmonary involvement: EPI and PAH
24. · Interstitial Lung Disease (EPI-ES)
25. · Pulmonary Arterial Hypertension (PAH-ES)
26. Sclerodermic Renal Crisis (SRC)
27. · Pathophysiology of CRE
28. · Clinical Presentation and Diagnostic Criteria
29. · Risk Factors for CRE
30. Cardiac Affectation
31. Gastrointestinal involvement
32. · Esophageal Involvement
33. · Gastric involvement
34. · Small Intestine Affectation
35. · Involvement of the Colon and Rectum
36. ACR/EULAR Criteria 2013
37. · VEDOSS: Very Early Diagnosis of SSc
38. Autoantibodies and Capillaroscopy
39. · Autoantibodies in SSc: Diagnostic and Prognostic Table
40. Treatment of Raynaud's and Digital Ulcers
41. · General Measures for the FR in ES
42. · Step Pharmacological Treatment of RF
43. · Local Treatment of Digital Ulcers
44. Treatment of ES-ILD
45. · First Line: Mycophenolate Mofetil (MMF)
46. · Second Line: Cyclophosphamide IV
47. · Nintedanib: The Antifibrotic
48. · Tocilizumab in EPI-ES
49. · Bone Marrow / Hematopoietic Stem Cell Transplantation (BCTMH)
50. Treatment of PAH-ES
51. · Risk Assessment and Stratification
52. · Treatment of ES-PAH by Drug Class
53. Sclerodermic Renal Crisis: ACEI and Management
54. · CRE Acute Management Protocol
55. · What Happens if CRE Occurs with Normal BP (Normotensive SRC)?
56. Prognosis, Comorbidities and Outlook
57. · Mortality and Cause of Death in ES
58. · Structured ES Monitoring (EUSTAR/SENSAR)
59. · Poor Prognostic Factors